Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this underperformance to price-driven volume declines, particularly following the loss of a major U.S. WIC contract and ongoing consumer price sensitivity. CEO Robert Ford acknowledged the need for a shift, stating, “This path is not sustainable long-term, so we began to make changes in the fourth quarter.” The company also cited higher manufacturing costs in nutrition that have yet to be offset, resulting in a cautious tone around near-term growth in this key division.
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released on January 21, 2026, the New Brunswick-based titan signaled a definitive pivot toward high-growth markets in oncology and cardiovascular technology. Despite
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence (AI)-integrated imaging software. This strategic realignment resulted in a massive $25.7 billion year-over-year jump in deal value for the diagnostics and
Healthcare product and device company Abbott Laboratories (NYSE:ABT) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit of $1.50 per share was in line with analysts’ consensus estimates.
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting bottom-line expectations for earnings per share, the healthcare giant reported a significant revenue miss that spooked investors, driven primarily by
Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT)
fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's expectations.
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an adjusted earnings per share (EPS) of $1.50—narrowly edging out the $1.49 consensus estimate—the medical device giant’
Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit of $1.50 per share was in line with analysts’ consensus estimates.
Healthcare product and device company Abbott Laboratories (NYSE:ABT)
will be announcing earnings results tomorrow before the bell. Here’s what to look for.
Healthcare product and device company Abbott Laboratories (NYSE:ABT)
will be reporting earnings this Thursday before market open. Here’s what to look for.
